Diagnostic methods for acute ischemic disease using activated hepcidin as an indicator
    2.
    发明授权
    Diagnostic methods for acute ischemic disease using activated hepcidin as an indicator 失效
    使用活化的铁调素作为指标的急性缺血性疾病的诊断方法

    公开(公告)号:US08187827B2

    公开(公告)日:2012-05-29

    申请号:US12601955

    申请日:2008-05-30

    申请人: Naohisa Tomosugi

    发明人: Naohisa Tomosugi

    IPC分类号: G01N33/55

    摘要: An objective of the present invention is to provide methods of testing for acute ischemic diseases using active hepcidin as an indicator, methods for determining the timing to administer an agent for treating the disease, and kits for these methods. To accomplish the objective, the present inventors analyzed the serum proteome patterns characteristic of acute myocardial infarction patients using SELDI-TOF-MS. As a result, it was found that hepcidin-20 has a very high correlation with acute myocardial infarction. Furthermore, the present inventors discovered that at the time of disease onset, the blood concentration of hepcidin-20 rises sharply in particular, and shows high levels within six hours, especially four hours of onset. The present invention enables early diagnosis of acute ischemic diseases.

    摘要翻译: 本发明的目的是提供使用活性铁调素作为指标来测试急性缺血性疾病的方法,用于确定施用治疗疾病的药剂的时间的方法,以及这些方法的试剂盒。 为了达到目的,本发明人使用SELDI-TOF-MS分析了急性心肌梗死患者血清蛋白质组学特征。 结果发现,hepcidin-20与急性心肌梗死的相关性非常高。 此外,本发明人发现,在疾病发病时,铁调素-20的血药浓度特别上升,在6小时以上,特别是4小时开始时显示高水平。 本发明能够早期诊断急性缺血性疾病。

    Methods for screening insulin-sensitizing agents
    3.
    发明授权
    Methods for screening insulin-sensitizing agents 失效
    筛选胰岛素敏化剂的方法

    公开(公告)号:US07556926B2

    公开(公告)日:2009-07-07

    申请号:US10515720

    申请日:2003-05-22

    CPC分类号: C07K14/47 A61K31/7088

    摘要: A compound or its salt inhibiting the activity of a protein having an amino acid sequence which is the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, an extracellular domain of the protein above, an antibody, an antisense polynucleotide, etc. are usable as insulin-sensitizing agents and preventives and/or remedies for diabetes, obesity, hyperlipemia, arteriosclerosis, hypertension, heart disease, and so on.

    摘要翻译: 抑制具有与SEQ ID NO:1表示的氨基酸序列相同或基本相同的氨基酸序列的蛋白质的活性的化合物或其盐,上述蛋白质的细胞外结构域,抗体 ,反义多核苷酸等可用作糖尿病,肥胖症,高脂血症,动脉硬化,高血压,心脏病等的胰岛素敏化剂和预防剂和/或治疗药物。

    Human tumor necrosis factor TR21 and methods based thereon
    6.
    发明授权
    Human tumor necrosis factor TR21 and methods based thereon 有权
    人肿瘤坏死因子TR21及其基础的方法

    公开(公告)号:US07112410B1

    公开(公告)日:2006-09-26

    申请号:US10229352

    申请日:2002-08-28

    IPC分类号: G01N33/55

    摘要: The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity. The invention further relates to the treatment, diagnosis, or prognosis of autoimmune diseases or disorders including Sjogren's syndrome using TR21 polynucleotides, polypeptides, agonists or antagonists.

    摘要翻译: 本发明涉及TR21多肽。 特别地,提供编码人TR21蛋白的分离的核酸分子。 还提供TR21多肽,载体,宿主细胞和用于制备它的重组方法。 本发明还涉及用于鉴定TR21活性的激动剂和拮抗剂的筛选方法。 本发明还涉及使用TR21多核苷酸,多肽,激动剂或拮抗剂的自身免疫疾病或病症包括干燥综合征的治疗,诊断或预后。

    Monoclonal antibody
    7.
    发明授权
    Monoclonal antibody 失效
    单克隆抗体

    公开(公告)号:US06967082B1

    公开(公告)日:2005-11-22

    申请号:US09890949

    申请日:2000-02-03

    申请人: Johan Stenflo

    发明人: Johan Stenflo

    IPC分类号: C07K16/38 G01N33/55

    CPC分类号: C07K16/38 Y10T436/105831

    摘要: The present invention relates to a monoclonal antibody suitable for monitoring the activity of systems involving protein C inhibitor, a method for preparation of the monoclonal antibody, a method for monitoring the activity of systems involving protein C inhibitor and a method for diagnosis of e.g. venous thrombosis, wherein the monoclonal antibody is utilized. The monoclonal antibody is suitable for monitoring the activity of systems involving protein C inhibitor, and it has specific affinity for both i) a complex between a serine proteinase and an inhibitor thereof, and ii) a cleaved and uncomplexed form of the inhibitor, but has substantially no specific affinity for the inhibitor in its uncleaved and uncomplexed form; or a derivative thereof having the same biological activity.

    摘要翻译: 本发明涉及适用于监测涉及蛋白C抑制剂的系统的活性的单克隆抗体,单克隆抗体的制备方法,用于监测涉及蛋白C抑制剂的系统的活性的方法和用于诊断例如抗体的方法。 静脉血栓形成,其中使用单克隆抗体。 单克隆抗体适合于监测涉及蛋白C抑制剂的系统的活性,并且它对i)丝氨酸蛋白酶和其抑制剂之间的复合物具有特异性亲和力,和ii)抑制剂的切割和非复合形式,但具有 基本上没有对其未裂解和未络合形式的抑制剂的特异性亲和力; 或其衍生物具有相同的生物活性。

    Formation of superfibronectin by BBK32 and uses therefor
    9.
    发明授权
    Formation of superfibronectin by BBK32 and uses therefor 失效
    通过BBK32形成超纤连蛋白,并用于此

    公开(公告)号:US07824868B2

    公开(公告)日:2010-11-02

    申请号:US12148389

    申请日:2008-04-18

    IPC分类号: G01N33/55 A61K38/16

    摘要: Provided herein is a method for inducing formation of a conformationally distinct superfibronectin by contacting plasma fibronectin with BBK32 protein or a BBK32 peptide and the BBK32-induced superfibronectin so formed. Also provided are methods of inhibiting endothelial cell proliferation, of treating pathophysiological conditions associated with endothelial cell proliferation and of inhibiting angiogenesis therein using the BBK32 protein, BBK32 peptide or the BBK32-induced superfibronectin.

    摘要翻译: 本文提供通过使血浆纤连蛋白与BBK32蛋白或BBK32肽接触形成的构象不同的超纤连结蛋白和由此形成的BBK32诱导的超纤连结蛋白的方法。 还提供了使用BBK32蛋白,BBK32肽或BBK32诱导的超纤连蛋白来抑制内皮细胞增殖,治疗与内皮细胞增殖相关的病理生理条件和抑制血管生成的方法。